

- **Name:** Sadahisa Ogasawara
 - **Current Position & Affiliation:** Associate professor, Department of Gastroenterology, Graduate School of Medicine, Chiba University
 - **Country:** Japan
-

• **Educational Background:**

M.D., Chiba University School of Medicine, 2004

Residency, Chiba University Hospital, 2004–2006

Ph.D. in Medical Science, Graduate School of Medical and Pharmaceutical Sciences, Chiba University, 2012

• **Professional Experience:**

Apr 2022 – Present

Associate Professor, Department of Gastroenterology, Graduate School of Medicine, Chiba University

Sep 2018 – Mar 2022

Associate Professor, Translational Research and Development Center, Chiba University Hospital

Apr 2016 – Aug 2018

Assistant Professor, Clinical Research Center, Chiba University Hospital

Nov 2013 – Mar 2016

Assistant Professor, Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University

• **Professional Organizations:**

Board Certified Specialist and Councilor, Japanese Society of Gastroenterology

Board Certified Specialist and Councilor, Japan Society of Hepatology

Board Certified Specialist, Japanese Society of Internal Medicine

Member, Japanese Society of Medical Oncology

Member, Japanese Society of Clinical Oncology

Member, American Society of Clinical Oncology (ASCO)

Member, European Society for Medical Oncology (ESMO)

Member, International Liver Cancer Association (ILCA)

• **Main Scientific Publications:**

1. Maruta S, **Ogasawara S (corresponding)**, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N: Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2020:382-396.
2. Ueshima K, **Ogasawara S (equally contribution, corresponding)**, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Ooka Y,

- Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M: Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. *Liver Cancer* 2020;9:583-595.
3. Koroki K, **Ogasawara S (corresponding)**, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N: Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. *Liver Cancer*. 2020:596-612.
 4. Koroki K, Kanogawa N, Maruta S, **Ogasawara S (corresponding)**, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. *Liver Cancer*. 2021;10(5):473-484.
 5. Kobayashi K, **Ogasawara S (corresponding)**, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. *Liver Cancer*. 2021;11(1):48-60.
 6. Kobayashi K, **Ogasawara S (corresponding)**, Maruta S, Okubo T, Itokawa N, Haga Y, Seko Y, Moriguchi M, Watanabe S, Shiko Y, Takatsuka H, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Inaba Y, Ikeda M, Okabe S, Morimoto N, Itoh Y, Nakamura K, Ito K, Azemoto R, Atsukawa M, Itobayashi E, Kato N. A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study. *Clin Cancer Res*. 2023 Oct 5.
 7. Koroki K, **Ogasawara S (corresponding)**, Izai R, Yonemoto T, Akatsuka T, Miwa C, Yumita S, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakamoto S, Nakada S, Sakai N, Yokoyama, Ohtsuka M, Kato N. Comprehensive analysis of radiologic cancer-free status through various treatment approaches in advanced-stage hepatocellular carcinoma. *Liver Cancer*. 2024. Nov 13;14(3):286-301.
 8. Inoue M, **Ogasawara S (corresponding)**, Kobayashi K, Okubo T, Itokawa N, Obu M, Fujimoto K, Unozawa H, Yumita S, Fujiwara K, Nakagawa M, Kanzaki H, Koroki K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakamoto S, Nagashima K, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Kato N. Assessment of macrovascular invasion in advanced hepatocellular carcinoma: clinical implications and treatment outcomes with systemic therapy. *Liver Cancer*. 2024 May 21;14(1):8-18.
 9. Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, **Ogasawara S**, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutkus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. *Lancet*. 2025;405:203-215.